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TO THE EDITOR
Fibrosis is a pathologic process in which
deposition of abnormal extracellular
matrix by fibroblasts leads to the loss
of normal tissue structure and function.
In skin, fibrosis is associated with several
diseases, including systemic sclerosis,
localized scleroderma, nephrogenic sys-
temic fibrosis, and keloid scars. Cur-
rently, effective targeted therapies to
reverse or prevent fibrosis are lacking.
Canonical Wnt/b-catenin signaling
is essential for survival and specifica-
tion of dermal fibroblasts during devel-
opment (Ohtola et al., 2008) and has
recently been implicated as a profibro-
tic pathway in skin (Lam and Gottardi,
2011). Central to this pathway is the
nuclear translocation of stabilized b-
catenin for transcriptional regulation of
cell type–specific target genes (van
Amerongen and Nusse, 2009). Impor-
tantly, stabilization of b-catenin de-
pends upon inhibition of GSK3-b via
canonical Wnt signaling or indirect
mechanisms (Bowley et al., 2007).
Evidence for aberrantly increased Wnt/
b-catenin signaling activity has been
observed in systemic sclerosis skin,
keloid scars, and desmoid tumors, as
well as in the tight-skin (tsk1/þ ),
bleomycin-induced, and GSK3-b inhi-
bitor-induced mouse models of skin
fibrosis (Alman et al., 1997; Sato,
2006; Bowley et al., 2007; Bayle
et al., 2008; Bergmann et al., 2011;
Akhmetshina et al., 2012; Beyer et al.,
2012; Wei et al., 2012). Wnt signaling
activation has also been implicated in
thickening of the tsk1/þ mouse hypo-
dermis region and in transdifferentia-
tion of adipocytes to myofibroblasts,
leading to skin fibrosis (Bayle et al.,
2008; Wei et al., 2011; Akhmetshina
et al., 2012), but the role of hypodermal
fibroblasts in skin fibrosis remains un-
clear. Recent studies have uncovered a
potential profibrotic mechanism for
Wnt signaling by which a complex
interplay between b-catenin and trans-
forming growth factor-b signaling reg-
ulates type I collagen alpha-1 chain
(Col1a1) mRNA expression in fibro-
blasts in vitro and collagen accumula-
tion in the skin of experimental models
of fibrosis (Akhmetshina et al., 2012;
Wei et al., 2012). Collectively, these
data demonstrate that the Wnt/b-cate-
nin pathway can interact with trans-
forming growth factor-b signaling to
mediate fibrosis.
Here, we show that skin affected by
localized scleroderma (morphea) has an
increased percentage of nuclear b-cate-
nin-positive dermal fibroblasts com-
pared with healthy control skin in
papillary (n¼4, P¼0.04; Figure 1a
and c) and reticular dermis (n¼1;
Figure 1b and c). This finding is
consistent with the recent observation
of increased nuclear b-catenin in der-
mal fibroblasts of patients with systemic
sclerosis (Beyer et al., 2012; Wei et al.,
2012). Thus, our data contribute to the
growing body of evidence that supports
a common role for b-catenin activity in
dermal fibroblasts across multiple fibro-
tic skin diseases.
On the basis of this observation, we
investigated the sufficiency of sustained
dermal fibroblast b-catenin activity for
fibrogenesis. We used the tamoxifen-
dependent HoxB6Cre (HoxB6Cre-ERT1)
line to conditionally activate the R26R-
YFP lineage tracer and remove exon 3
of endogenous b-catenin (b-cateninstab/þ ),
resulting in the stabilization of
b-catenin in ventral dermal fibroblasts
(Harada et al., 1999; Srinivas et al.,
2001; Nguyen et al., 2009). PregnantAbbreviations: CTGF, connective-tissue growth factor; E, embryonic; P, postnatal
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mice carrying control HoxB6Cre-ERT1/
þ ; R26R-YFP/þ and HoxB6Cre-ERT1/
þ ; R26R-YFP/þ ; b-cateninstab/þ con-
ditional mutant embryos were given 1
dose (3mg/40 g body weight) of tamo-
xifen at E15.5, E16.5, or E17.5 to induce
expression of stabilized b-catenin and
yellow fluorescent protein (YFP). YFP-
positive recombined cells contributed
to fibroblasts in the dermis and hypo-
dermis and not to the epidermis,
skeletal muscle, adipose, or endothelial
lineages in postnatal ventral skin (Figure
2a, data not shown). HoxB6 Cre-ERT1;
R26R-YFP; b-cateninstab/þ mutant cells
showed a morphology consistent with
fibroblasts in the dermis and the hypo-
dermis until the latest time point ana-
lyzed (P50; Supplementary Figure S1a
online).
HoxB6Cre-ERT1/þ ; R26R-YFP; b-
cateninstab/þ mutant skin displayed a
progressive increase in relative thickness
of the mutant dermis and hypodermis
compared with HoxB6Cre-ERT1/þ ;
R26R-YFP control skin. Although the
thickened mutant dermis appeared his-
tologically similar to age-matched con-
trols, the mutant hypodermal tissue was
characterized by invasion of adjacent
subcutaneous muscle and adipose tissue
by cords of spindle-shaped cells (Figure
2b and Supplementary Figure S1b on-
line). Measurements of mutant skin
sections showed a 1.4-fold thicker
dermis and a marked 3.8-fold expansion
of hypodermal thickness compared with
littermate controls (Figure 2c). There
was a significantly greater percentage
of nuclear b-catenin-positive fibroblasts
in mutant dermis and hypodermis com-
pared with the control dermis (Figure 2d
and Supplementary Figure S1c online).
Fibroblast proliferation was signifi-
cantly increased in mutant hypodermis
compared with the control and mutant
dermis (Figure 2e).
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Figure 1. Nuclear b-catenin immunoreactivity in skin affected by localized scleroderma. Brightfield
immunohistochemistry using anti-b-catenin antibody (BD Bioscience, San Jose, CA, 1:100) was
performed on sections of affected skin from four localized scleroderma patients and normal skin from four
healthy controls. (a) Representative images with insets showing details from papillary dermis of healthy
control and localized scleroderma–affected skin. b-Catenin-positive nuclei are indicated by filled
arrowheads. (b) Reticular dermis of control (representative image) and localized scleroderma skin that
had fibroblasts in the reticular dermis. (c) The percentage of nuclear b-catenin-positive fibroblasts in
papillary and reticular dermis was calculated from 2–3 high-power fields for each sample. Scale bar¼ 50mm.
Figure 2. Characterization of fibrotic skin phenotype. (a) Immunofluorescence using anti-green fluorescent protein antibody against yellow fluorescent
protein (YFP), P50 (Aves Labs, Tigard, OR, 1:250). Epi, epidermis; Hf, hair follicle. (b) Hematoxylin and eosin-stained skin at P4, P22, and P50. Adip, adipose;
Hd, hypodermis. (c) P50 dermal and hypodermal thickness quantified by Photoshop measurement tool; n¼15 controls, 15 mutants. (d) Percentage of nuclear
b-catenin-positive fibroblasts in P50 skin; n¼ 7 controls, 7 mutants; P¼ 0.002. HDF, hypodermal fibrosis. (e) P22 cell proliferation assessed by anti-Ki67
immunofluorescence (Abcam, Cambridge, MA, 15580, 1:500); n¼ 3 controls, 3 mutants. (f) Hydroxyproline content per 5-mm punch biopsy of P50 and P100
control and mutant ventral skin. (g) Masson’s trichrome stain of P50 skin. (h) Anti-connective-tissue growth factor (CTGF; Abcam 6992, 1:400) brightfield
immunohistochemistry performed on P21 skin (n¼ 5 each for controls and mutants). Arrowheads indicate CTGF-positive cells. (i) Brightfield immuno-
histochemistry of endothelial cells in P50 skin (anti-MECA-32 antibody, Developmental Studies Hybridoma Bank, University of lowa, lowa City, IA, 1:10). All
corresponding images were photographed at the same magnification. Quantification of marker expression based on three high-power fields per sample.
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We next proceeded to characterize
the thickened dermis and hypodermis
in the activated b-catenin mutant skin.
Quantification of collagen by hydro-
xyproline assay demonstrated 2.3- and
1.8-fold increases in collagen content
of mutant skin at P50 and P100,
respectively (Figure 2f). Accordingly,
collagen accumulation was apparent
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in the mutant dermis and hypodermis
by Masson’s trichrome stain (Figure 2g).
Connective-tissue growth factor (CTGF)/
CCN2, a marker of fibrosis (Holmes
et al., 2001), was expressed by dermal
and hypodermal fibroblasts of P21
control and mutant skin, and was high-
er in the expanded mutant hypodermis
(30.9±8.7% of fibroblasts) compared
with the overlying dermis (17.8±5.1%;
P¼0.01; Figure 2h). Although there
was no significant difference in the
quantity or appearance of blood vessels
between P50 control and mutant dermis
(quantification not shown), there was
a pronounced absence of blood vessels
in the thickened mutant hypodermis
by MECA-32 immunohistochemistry
(Figure 2i).
In conclusion, taken together with
previous observations in other fibrotic
skin diseases, increased nuclear b-
catenin immunoreactivity in skin af-
fected by localized scleroderma
strongly suggests a profibrotic role for
b-catenin in dermal fibroblasts. Our
in vivo model of activated b-catenin
in skin fibroblasts holds important im-
plications for several human diseases
that involve skin fibrosis, and our
findings are consistent with recent
studies (Akhmetshina et al., 2012;
Beyer et al., 2012; Wei et al., 2012).
We have shown that restricted consti-
tutive activation of b-catenin in a subset
of mouse skin fibroblasts is sufficient for
spontaneous, progressive thickening of
the hypodermis and dermis accompa-
nied by increased cell proliferation. In
particular, the increased percentage
of proliferating and CTGF-expressing
fibroblasts in the hypodermal region
compared with the overlying dermis of
the activated b-catenin mutant skin
demonstrates that b-catenin activity in
a distinct subpopulation of fibroblasts
can substantially contribute to an overt
skin fibrosis phenotype. This finding
expands upon previous studies that
have suggested a role for Wnt/b-catenin
in the hypodermis of fibrotic skin (Bayle
et al., 2008; Wei et al., 2011; Akhmet-
shina et al., 2012). Additional studies
are required to determine the genetic
interactions between b-catenin and
other profibrotic signaling pathways
during the development of b-catenin-
dependent skin fibrosis. We will use the
activated b-catenin model to define
interactions between b-catenin and
other important mediators of fibrosis
such as transforming growth factor-b/
Smad2/3, CTGF, PTEN, and MAPK/ERK
and to identify target genes that
functionally mediate the profibrotic
effects of b-catenin activation. Ulti-
mately, these studies will be critical
for developing novel therapeutic ap-
proaches to prevent and treat fibrotic
skin diseases.
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